Deborah Harland
SR One is the independent corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested over $680 million in the biotech space and has a current portfolio of approximately 30 private and public companies. For more information, visit www.srone.com
